CorMedix (CRMD) Chief Legal Officer receives 72,820 RSUs, withholds shares for tax

Rhea-AI Filing Summary

CorMedix Inc.'s Chief Legal Officer Beth Zelnick Kaufman reported equity compensation activity in the company’s common stock. On 01/23/2026 she received an award of 72,820 restricted stock units at a price of $0.00 per unit, each representing one share of common stock.

The restricted stock units vest 25% on the grant date and, subject to continued employment, 25% on each of the first, second, and third anniversaries of the grant date. On the same day, 8,803 shares were withheld at $7.27 per share, typically for tax obligations, leaving her with 233,102 directly owned shares after the reported transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zelnick Kaufman Beth

(Last) (First) (Middle)

C/O CORMEDIX INC.,

389 INTERPACE PKWY, SUITE 450

(Street)

PARSIPPANY NJ 07054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		A		72,820	A	$0.00(1)	241,905	D
Common Stock	01/23/2026		F		8,803	D	$7.27	233,102	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units granted on 01/23/2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Beth Zelnick Kaufman	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CorMedix (CRMD) disclose for its Chief Legal Officer?

CorMedix disclosed that Chief Legal Officer Beth Zelnick Kaufman received 72,820 restricted stock units on 01/23/2026. Each unit represents one share of common stock, forming part of her equity compensation and subject to a multi-year vesting schedule tied to continued employment.

How many CorMedix (CRMD) restricted stock units were granted on 01/23/2026?

On 01/23/2026, 72,820 restricted stock units were granted to the Chief Legal Officer. Each restricted stock unit converts into one share of CorMedix common stock, providing long-term equity incentives that vest over several years instead of immediate cash compensation or unrestricted shares.

What is the vesting schedule for the 72,820 CorMedix (CRMD) restricted stock units?

The 72,820 restricted stock units vest 25% on the grant date, then 25% on each of the first, second, and third anniversaries. Continued employment is required for the later vesting dates, aligning the executive’s incentives with CorMedix’s long-term performance and retention goals.

Why were 8,803 CorMedix (CRMD) shares reported with transaction code F at $7.27?

The 8,803 shares with code F at $7.27 per share reflect shares withheld to cover obligations such as taxes related to the equity award. This is a common method where the company withholds shares instead of the executive paying cash for the associated tax liability.

How many CorMedix (CRMD) shares does the Chief Legal Officer hold after these transactions?

After the reported transactions on 01/23/2026, the Chief Legal Officer directly owns 233,102 shares of CorMedix common stock. This figure reflects both the new restricted stock unit grant and the share withholding event recorded in the same Form 4 filing.

What role does Beth Zelnick Kaufman hold at CorMedix (CRMD) according to this Form 4?

Beth Zelnick Kaufman is identified as the Chief Legal Officer of CorMedix Inc. in the Form 4. Her position qualifies her as a Section 16 officer, requiring public reporting of her transactions in the company’s equity securities for transparency to investors.